[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649290":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":24,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":80,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Hangzhou Sciwind Biosciences Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ecnoglutide Injection","EXPERIMENTAL","Once weekly",[13],"Drug: Ecnoglutide Injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: placebo with matching volume",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","subcutaneous injection",[9],null,{"type":21,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"placebo with matching volume",[15],[29],{"name":30,"affiliation":31,"role":32},"Weihua XU","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Yao Li","CONTACT","010-67889255","yao.li@sciwindbio.com",[40],{"facility":31,"status":24,"city":41,"state":42,"zip":24,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Wuhan","Hubei","China","CN",{"type":46,"coordinates":47},"Point",[48,49],114.26667,30.58333,{"lat":49,"lon":48},[52],{"name":53,"role":36,"phone":24,"phoneExt":24,"email":54},"Weihua XU, Dr","xuweihua@hust.edu.cn",{"type":56,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100649290","phase-3-a-study-of-econoglutide-injection-in-obese-participants-with-knee-osteoarthritis-koa-100649290",false,"NCT07734311","A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm\\^2;\n2. The target knee must meet the diagnostic criteria of American College of Rheumatology (ACR) for knee osteoarthritis (clinical and radiological), with moderate radiographic changes (Kellgren-Lawrence grade 2 or 3). The target knee is defined as the knee with the most symptomatic knee at screening period; if pain in both knees are equal, the target knee will be the most dominant leg (preferred leg);\n3. Prior to screening, target knee pain lasting more than 12 weeks, and according to participant's self-report or medical history at screening, target knee pain lasting more than 15 days in the past month;\n4. At screening and prior to randomization, WOMAC pain score (NRS 0-10) of the target knee must be between 4 and 9 (to avoid bias in reporting, participants must not be informed of the pain score used to determine eligibility for the study);\n5. Self-reported by the participant who has a history of unsuccessful weight loss attempt by diet and exercise.\n\nExclusion Criteria:\n\n1. The target knee has undergone joint replacement surgery;\n2. The target knee has undergone arthroscopy within 12 months prior to screening;\n3. At the time of screening, the target knee joint has any clinical features and symptoms of other active infections or crystal-induced arthropathies, as well as any other active joint diseases that may interfere with assessment;\n4. The target knee has received intra-articular injections of hyaluronic acid, any other investigational drugs, or biologics within 3 months prior to screening; or has undergone any procedures that result in persistent sensory loss in the target knee (e.g., ablation) within 6 months prior to screening;\n5. Has received any intramuscular or oral corticosteroids (investigational or marketed) within 30 days prior to screening, or has received any intra-articular corticosteroid injections (investigational or marketed) in any joint within 90 days prior to screening;\n6. History of joint instability in either knee within 12 months prior to screening, such as anterior cruciate ligament rupture or recent trauma;\n7. History of any other potentially causative and\u002For confounding diseases, including Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease-associated arthritis, sarcoidosis, amyloidosis, or fibromyalgia;\n8. Presence of symptomatic hip osteoarthritis at the time of screening, with the exception of those who have undergone hip replacement surgery;\n9. Conditions that may interfere with the assessment of target knee pain during screening include, but are not limited to:\n\n   * Pain in any part of the lower limb or back equal to or more severe than the pain in the target knee;\n   * Pain radiating to the knee from other areas, such as hip pain affecting the knee or radicular pain;\n   * Chronic widespread pain (including neuropathic pain);\n10. Change of body weight \\>5% within 3 months prior to screening (selfreported);\n11. Diagnosis of diabetes (excluding gestational diabetes), or with a history of diabetic ketoacidosis or hyperosmolar state\u002Fcoma","ALL","18 Years","75 Years",{"count":68,"type":69},360,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.",[75,76],"Knee Osteoarthritis","Obesity",[78,79,76],"Ecnoglutide","KOA","NOT_YET_RECRUITING","2026-07-24",{"date":83,"type":84},"2026-07-29","ACTUAL",{"date":86,"type":69},"2026-07-31",{"date":88,"type":69},"2028-06-30",{"name":5,"class":6},1]